Trial Profile

A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MCLA-145 (Primary) ; Pembrolizumab (Primary)
Indications Anal cancer; B-cell lymphoma; Cervical cancer; Gastric cancer; Glioblastoma; Merkel cell carcinoma; Non-small cell lung cancer; Sarcoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Merus

Most Recent Events

11 Dec 2024 Status changed from active, no longer recruiting to completed.
03 Oct 2024 Planned number of patients changed from 118 to 238.
03 Oct 2024 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com